Drug
Racotumomab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Group | Anti-idiotype vaccine mAb |
| Mechanism of Action | Anti-idiotype vaccine |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No direct RT-interaction data; theoretical immunologic potentiation (RT-induced ICD/antigen release priming vaccine response) (Lu and Deng, Journal of Clinical Investigation, 2026; Yahia et al., Molecular Carcinogenesis, 2026). No DNA-level sensitization; any theoretical risk would be immune-mediated.
Data on this page refer exclusively to patients treated with
Racotumomab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Anti-idiotype vaccine mAb group page.